[
  {
    "ts": "2026-01-13T02:06:44+00:00",
    "headline": "Adaptive Biotechnologies Touts clonoSEQ MRD Growth, Targets Companywide Profitability in 2026",
    "summary": "Adaptive Biotechnologies (NASDAQ:ADPT) used a presentation at the J.P. Morgan healthcare conference to outline growth drivers for its clonoSEQ minimal residual disease (MRD) franchise and to describe a capital-disciplined strategy for its immune medicine (IM) unit, while also reiterating an expectat",
    "url": "https://www.marketbeat.com/instant-alerts/adaptive-biotechnologies-touts-clonoseq-mrd-growth-targets-companywide-profitability-in-2026-2026-01-12/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "6a47b310-4337-38a6-a42f-7234fb2398ba",
      "content": {
        "id": "6a47b310-4337-38a6-a42f-7234fb2398ba",
        "contentType": "STORY",
        "title": "Adaptive Biotechnologies Touts clonoSEQ MRD Growth, Targets Companywide Profitability in 2026",
        "description": "",
        "summary": "Adaptive Biotechnologies (NASDAQ:ADPT) used a presentation at the J.P. Morgan healthcare conference to outline growth drivers for its clonoSEQ minimal residual disease (MRD) franchise and to describe a capital-disciplined strategy for its immune medicine (IM) unit, while also reiterating an expectat",
        "pubDate": "2026-01-13T02:06:44Z",
        "displayTime": "2026-01-13T02:06:44Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/baa5b0d6d1008ef08fbab74e80859778",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Adaptive Biotechnologies logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vl3KxAbO6Qy1kY4gwcWiQw--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/baa5b0d6d1008ef08fbab74e80859778.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/k0aX39WhsUnMUyzB.8sxJg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/baa5b0d6d1008ef08fbab74e80859778.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/adaptive-biotechnologies-touts-clonoseq-mrd-growth-targets-companywide-profitability-in-2026-2026-01-12/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/adaptive-biotechnologies-touts-clonoseq-mrd-020644870.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ADPT"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-13T11:00:20+00:00",
    "headline": "Pfizer Inc. (NYSE:PFE) is favoured by institutional owners who hold 66% of the company",
    "summary": "Key Insights Given the large stake in the stock by institutions, Pfizer's stock price might be vulnerable to their...",
    "url": "https://finance.yahoo.com/news/pfizer-inc-nyse-pfe-favoured-110020551.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "64d9b4ee-82fe-36a2-9d94-b93d5871bdb7",
      "content": {
        "id": "64d9b4ee-82fe-36a2-9d94-b93d5871bdb7",
        "contentType": "STORY",
        "title": "Pfizer Inc. (NYSE:PFE) is favoured by institutional owners who hold 66% of the company",
        "description": "",
        "summary": "Key Insights Given the large stake in the stock by institutions, Pfizer's stock price might be vulnerable to their...",
        "pubDate": "2026-01-13T11:00:20Z",
        "displayTime": "2026-01-13T11:00:20Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QSfydsi7Q.1zNEN99DbEyw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hi2p7oczHh8yTJraqZcczg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-inc-nyse-pfe-favoured-110020551.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-inc-nyse-pfe-favoured-110020551.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-13T10:24:00+00:00",
    "headline": "AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.",
    "summary": "AbbVie  has agreed to cut some drug prices and invest $100 billion in the U.S. in exchange for an exemption from some tariffs.  The pharma company said in a statement late Monday that it had struck a deal with the Trump administration to lower Medicaid prices and pour the money into U.S. research and development.  AbbVie will also expand its direct-to-patient offerings of certain drugs on the government portal TrumpRx.",
    "url": "https://www.barrons.com/articles/abbvie-stock-trump-tariffs-deal-4f08ec87?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "1d0e3ef9-8bce-3c03-92ed-9f3f6b25fa5f",
      "content": {
        "id": "1d0e3ef9-8bce-3c03-92ed-9f3f6b25fa5f",
        "contentType": "STORY",
        "title": "AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.",
        "description": "",
        "summary": "AbbVie  has agreed to cut some drug prices and invest $100 billion in the U.S. in exchange for an exemption from some tariffs.  The pharma company said in a statement late Monday that it had struck a deal with the Trump administration to lower Medicaid prices and pour the money into U.S. research and development.  AbbVie will also expand its direct-to-patient offerings of certain drugs on the government portal TrumpRx.",
        "pubDate": "2026-01-13T10:24:00Z",
        "displayTime": "2026-01-13T10:24:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/1d0e3ef9-8bce-3c03-92ed-9f3f6b25fa5f/abbvie-strikes-a-100-billion.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/0a2845aa6b4185d51e8f8c6cc2b1e7a8",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uprYtz96.huIUAIJcxlT7w--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/0a2845aa6b4185d51e8f8c6cc2b1e7a8.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LhuGYFvbZhLBqQD88UWabQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/0a2845aa6b4185d51e8f8c6cc2b1e7a8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/abbvie-stock-trump-tariffs-deal-4f08ec87?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-13T12:48:28+00:00",
    "headline": "Tempus AI (TEM) Soars 15% on $1.1-Billion Deal",
    "summary": "We recently published 10 Stocks With Crazy Gains. Tempus AI Inc. (NASDAQ:TEM) was one of the top performers on Monday. Tempus AI snapped a two-day losing streak on Monday, soaring by as much as 15 percent to $76.33 apiece, as investors took heart from a strong demand for its services, having bagged $1.1 billion in […]",
    "url": "https://finance.yahoo.com/news/tempus-ai-tem-soars-15-124828137.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "8cd6eab2-2b32-3342-b8c7-afc388628b1c",
      "content": {
        "id": "8cd6eab2-2b32-3342-b8c7-afc388628b1c",
        "contentType": "STORY",
        "title": "Tempus AI (TEM) Soars 15% on $1.1-Billion Deal",
        "description": "",
        "summary": "We recently published 10 Stocks With Crazy Gains. Tempus AI Inc. (NASDAQ:TEM) was one of the top performers on Monday. Tempus AI snapped a two-day losing streak on Monday, soaring by as much as 15 percent to $76.33 apiece, as investors took heart from a strong demand for its services, having bagged $1.1 billion in […]",
        "pubDate": "2026-01-13T12:48:28Z",
        "displayTime": "2026-01-13T12:48:28Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/4edc292b1dcbd797c07f522ebf66f3cd",
          "originalWidth": 768,
          "originalHeight": 512,
          "caption": "Tempus AI (TEM) Soars 15% on $1.1-Billion Deal",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wpXHllSshAhvRjKQLWZ8dQ--~B/aD01MTI7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4edc292b1dcbd797c07f522ebf66f3cd.cf.webp",
              "width": 768,
              "height": 512,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/V0NnFlegXm2HaeSZe_vD3A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4edc292b1dcbd797c07f522ebf66f3cd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/tempus-ai-tem-soars-15-124828137.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/tempus-ai-tem-soars-15-124828137.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "TEM"
            },
            {
              "symbol": "DSKYF"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "GSK"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "WHWK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-13T11:53:00+00:00",
    "headline": "Health Care Roundup: Market Talk",
    "summary": "Find insight on Bristol-Myers Squibb, Pfizer, Johnson & Johnson and more in the latest Market Talks covering Health Care.",
    "url": "https://www.wsj.com/business/health-care-roundup-market-talk-ab91a0b0?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "d5f617d3-f057-3b8c-9ae7-8e2e48f7211e",
      "content": {
        "id": "d5f617d3-f057-3b8c-9ae7-8e2e48f7211e",
        "contentType": "STORY",
        "title": "Health Care Roundup: Market Talk",
        "description": "",
        "summary": "Find insight on Bristol-Myers Squibb, Pfizer, Johnson & Johnson and more in the latest Market Talks covering Health Care.",
        "pubDate": "2026-01-13T11:53:00Z",
        "displayTime": "2026-01-13T11:53:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/d5f617d3-f057-3b8c-9ae7-8e2e48f7211e/health-care-roundup-market.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/bd45e130fb5d221ae0c46fc72b2041d5",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ARM0GrkFQuANPgLprIGrwA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/bd45e130fb5d221ae0c46fc72b2041d5.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AsLL0hd96VZM1Aq90rZ1Kg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/bd45e130fb5d221ae0c46fc72b2041d5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/business/health-care-roundup-market-talk-ab91a0b0?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-13T14:06:19+00:00",
    "headline": "Jim Cramer Says “I’m a Eli Lilly Guy” When Asked About Viking Therapeutics",
    "summary": "Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the stocks Jim Cramer discussed, along with recent market rotation. When a caller asked about the stock, here’s what Cramer had to say in response: “Okay, no, look, I’m a Eli Lilly guy, okay? I’m going to stick with it. If I’m going to do Viking, I’m going […]",
    "url": "https://finance.yahoo.com/news/jim-cramer-says-m-eli-140619910.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "336d3ff3-872a-362b-a58e-5f83321f2ae9",
      "content": {
        "id": "336d3ff3-872a-362b-a58e-5f83321f2ae9",
        "contentType": "STORY",
        "title": "Jim Cramer Says “I’m a Eli Lilly Guy” When Asked About Viking Therapeutics",
        "description": "",
        "summary": "Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the stocks Jim Cramer discussed, along with recent market rotation. When a caller asked about the stock, here’s what Cramer had to say in response: “Okay, no, look, I’m a Eli Lilly guy, okay? I’m going to stick with it. If I’m going to do Viking, I’m going […]",
        "pubDate": "2026-01-13T14:06:19Z",
        "displayTime": "2026-01-13T14:06:19Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/92264ef32b70332cc4ea9283d978e1a6",
          "originalWidth": 6538,
          "originalHeight": 4359,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RYQ.uW7wwp9a4kdxC.OBbQ--~B/aD00MzU5O3c9NjUzODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/92264ef32b70332cc4ea9283d978e1a6.cf.webp",
              "width": 6538,
              "height": 4359,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2i4a98C_B2YJXhctyiN1Vw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/92264ef32b70332cc4ea9283d978e1a6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-says-m-eli-140619910.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-says-m-eli-140619910.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]